Combined autophagy and proteasome inhibition

Combined autophagy and HDAC inhibition

(2014) Devalingam Mahalingam et al.   Autophagy

Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma

(2014) Reshma Rangwala et al.   Autophagy

Combined MTOR and autophagy inhibition

(2014) Reshma Rangwala et al.   Autophagy

A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

(2014) Myrna R Rosenfeld et al.   Autophagy

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

(2013) P. G. Richardson et al.   BLOOD

Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo

(2013) Aluvia M. Escalante et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

(2013) Meletios Dimopoulos et al.   LANCET ONCOLOGY

Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma

(2012) Bo Hui et al.   CANCER

Blocking Autophagy Prevents Bortezomib-Induced NF-κB Activation by Reducing I-κBα Degradation in Lymphoma Cells

(2012) Li Jia et al.   PLoS One

Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency

(2012) Q. McAfee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Principles and Current Strategies for Targeting Autophagy for Cancer Treatment

(2011) R. K. Amaravadi et al.   CLINICAL CANCER RESEARCH

Macroautophagy and ERK phosphorylation counteract the anti-proliferative effect of proteasome inhibitor in gastric cancer cells

(2010) William Ka Kei Wu et al.   Autophagy

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

(2009) K. Dunleavy et al.   BLOOD

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition

(2009) G. Bianchi et al.   BLOOD

The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib

(2009) M. Milani et al.   CANCER RESEARCH

Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma

(2009) Sven de Vos et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy

(2009) W.-X. Ding et al.   MOLECULAR CANCER THERAPEUTICS

Bortezomib With or Without Irinotecan in Relapsed or Refractory Colorectal Cancer: Results From a Randomized Phase II Study

(2008) Peter S. Kozuch et al.   JOURNAL OF CLINICAL ONCOLOGY

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

(2008) R A Kyle et al.   LEUKEMIA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE